Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | TSHA | Common Stock | 7.27M | Oct 21, 2022 | Direct | F1 |
Id | Content |
---|---|
F1 | The securities are directly held by Audentes Therapeutics, Inc., a Delaware corporation, ("Audentes") a wholly owned direct subsidiary of Astellas US Holding, Inc., a Delaware corporation, ("Astellas US") which is in turn a wholly owned direct subsidiary of Astellas Pharma Inc., a corporation established under the laws of Japan ("Astellas"). Under SEC rules and regulations, each of Astellas and Astellas US may be deemed to have indirect beneficial ownership of the shares held by Audentes, which has direct beneficial ownership. |
Exhibit List Exhibit 24.1 - Power of Attorney (Astellas) Exhibit 24.2 - Power of Attorney (Audentes)